Latest On Compugen Ltd (CGEN):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-26 23:55 EST | News | Roche drives rival anti-TIGIT developers higher after cancer drug data | N/A |  |
| 2023-05-15 22:12 EST | News | Compugen Ltd. (CGEN) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-12 21:53 EST | News | Compugen Q1 2023 Earnings Preview | N/A | |
| 2023-02-28 02:59 EST | News | Compugen Ltd. (CGEN) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-02-27 12:59 EST | News | Compugen reports Q4 earnings; initiates FY23 cash burn guidance | N/A | |
| 2023-02-24 16:00 EST | News | Compugen Q4 2022 Earnings Preview | N/A | |
| 2022-12-06 17:12 EST | News | Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial | N/A | |
| 2022-11-16 09:39 EST | News | Compugen to get $7.5M milestone as AstraZeneca begins dosing in cancer drug study | N/A | |
| 2022-11-15 16:57 EST | News | Compugen Ltd. 2022 Q3 - Results - Earnings Call Presentation | N/A | |
| 2022-11-15 16:57 EST | News | Compugen Ltd. (CGEN) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-15 00:08 EST | News | Compugen GAAP EPS of -$0.14 misses by $0.01 | N/A | |
| 2022-11-12 02:48 EST | News | Compugen Q3 2022 Earnings Preview | N/A | |
| 2022-09-12 15:31 EST | News | Compugen appoints Alberto Sessa as CFO | N/A | |
| 2022-08-24 18:35 EST | News | Compugen gets Japanese patent for COM701, anti-PVRIG antibodies | N/A | |
| 2022-08-05 00:51 EST | News | Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-03 18:46 EST | News | Compugen Q2 2022 Earnings Preview | N/A | |
| 2022-05-16 10:01 EST | News | Compugen GAAP EPS of -$0.11 beats by $0.01 | N/A | |
| 2022-05-14 13:35 EST | News | Compugen Q1 2022 Earnings Preview | N/A | |
| 2022-02-25 06:02 EST | News | Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-24 10:19 EST | News | Compugen GAAP EPS of -$0.10 beats by $0.04 | N/A | |
| 2022-02-23 14:23 EST | News | Compugen Q4 2021 Earnings Preview | N/A | |
| 2022-01-18 18:58 EST | News | Compugen gets US patent for COM701 combo use in cancer | N/A | |
| 2021-11-12 18:41 EST | News | Compugen EPS beats by $0.05 | N/A | |
| 2021-11-12 18:41 EST | News | Compugen posts early Phase 1 data for anti-TIGIT antibody in advanced solid tumors | N/A | |
| 2021-11-12 18:40 EST | News | Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-11 23:20 EST | News | Bristol-Myers Squibb completes $20M investment in Compugen | N/A | |
| 2021-10-27 15:47 EST | News | Warning: CGEN is at high risk of performing badly | N/A | |
| 2021-10-05 01:38 EST | News | Compugen to receive $6M from AstraZeneca after dosing first patient in lung cancer trial | N/A | |
| 2021-09-21 14:42 EST | News | Compugen EPS beats by $0.01 | N/A | |
| 2021-08-20 00:43 EST | News | Compugen's bispecific antibody derived from COM902 to enter clinical development | N/A | |
| 2021-07-28 19:38 EST | News | Compugen posts Q2 results, provides cash position update | N/A | |
| 2021-07-28 19:37 EST | News | Compugen Ltd (CGEN) CEO Anat Cohen-Dayag on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-21 00:48 EST | News | Stocks To Watch: Spotlight On REITs, Apple, Chewy And GameStop | N/A | |
| 2021-07-21 00:46 EST | News | Compugen reports updated COM701 data from Phase 1 study at ASCO21 | N/A | |
| 2021-07-21 00:41 EST | News | Compugen gains on takeover speculation after iTeos Therapeutics deal | N/A | |
| 2021-07-21 00:22 EST | News | Dosing underway in Compugen's COM701/Opdivo Phase 1b cohort expansion study | N/A | |
| 2021-07-21 00:22 EST | News | Compugen (CGEN) Presents At TIGIT Pathway:Deep Dive in Cancer Immunotherapy Targets - Slideshow | N/A | |
| 2021-07-21 00:06 EST | News | Dosing underway in Compugen's Phase 1 COM902 combo study in advanced malignancies | N/A | |
| 2021-07-21 00:03 EST | News | Dosing underway in Compugen's mid-stage COM701 triple combo study | N/A | |
| 2021-04-27 14:14 EST | News | Compugen's COM902 demonstrates potential benefit in cancer | N/A | |
| 2021-03-01 07:24 EST | Analyst Rating | The Analyst Target Price has increased from $21.43 to $21.71. | Buy | |
| 2021-02-28 21:32 EST | News | Compugen: Serious Partnerships, Tremendous Potential, But Several Years To Wait | N/A | |
| 2021-02-27 03:19 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-26 07:20 EST | Earnings Estimate | An EPS average of -$0.69 is estimated for the 2022 year. | Sell | |
| 2021-02-26 07:20 EST | Earnings Estimate | An EPS average of -$0.13 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-02-25 22:25 EST | News | Compugen Ltd. (CGEN) CEO Anat Cohen-Dayag on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-02-25 00:10 EST | News | Compugen Q4 Earnings Preview | N/A | |
| 2021-02-24 11:17 EST | Analyst Rating | The Analyst Target Price has increased from $20.38 to $21.43. | Buy | |
| 2021-02-22 18:39 EST | News | Compugen expands deal with Bristol Myers for phase 1b COM701 combo study | N/A | |
| 2020-12-23 10:57 EST | News | Compugen earns $2M milestone under antibody development deal with AstraZeneca | N/A | |
About Compugen Ltd (CGEN):
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
General
- Name Compugen Ltd
- Symbol CGEN
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 68
- Fiscal Year EndDecember
- IPO Date2000-08-11
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryLife Sciences Tools & Services
- Gic SubIndustryLife Sciences Tools & Services
- Web URLhttp://www.cgen.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 354.18
- Price/Book (Most Recent Quarter) 6.22
- Enterprise Value Revenue 305.1
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.53
- Next Year EPS Estimate -$0.72
- Next Quarter EPS Estimate -$0.12
- Operating Margin -1575%
- Return on Assets -21%
- Return on Equity -38%
- Revenue 2 million
- Earnings Per Share -$0.45
- Revenue Per Share $0.03
- Gross Profit 1.94 million
- Quarterly Earnings Growth 0%
View More
Highlights
- Market Capitalization 686.11 million
- EBITDA -27295000
- PE Ratio -5.59
- Analyst Target Price $21.71
- Book Value Per Share $1.43
View More
Share Statistics
- Shares Outstanding 83.68 million
- Shares Float 83.6 million
- % Held by Insiders 38%
- % Held by Institutions 53.16%
- Shares Short 4.01 million
- Shares Short Prior Month 3.81 million
- Short Ratio 2.86
- Short % of Float 6%
- Short % of Shares Outstanding 5%
View More
Technicals
- Beta 2.39
- 52 Week High $19.9
- 52 Week Low $6.05
- 50 Day Moving Average 10.99
- 200 Day Moving Average 13.42
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Compugen Ltd (CGEN) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Compugen Ltd (CGEN) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-25 | $N/A | -$0.10 | -$0.10 | 1.38% |
| 2020-09-30 | 2020-11-05 | $N/A | -$0.09 | -$0.09 | -3.33% |
| 2020-06-30 | 2020-07-30 | $N/A | -$0.08 | -$0.11 | 23.81% |
| 2020-03-31 | 2020-05-06 | $N/A | -$0.10 | -$0.10 | 0% |
| 2019-12-31 | 2020-02-20 | $N/A | -$0.10 | -$0.11 | 6.28% |
| 2019-09-30 | 2019-11-11 | $N/A | -$0.10 | -$0.11 | 4.76% |
| 2019-06-30 | 2019-08-05 | $N/A | -$0.10 | -$0.15 | 31.03% |
| 2019-03-31 | 2019-05-20 | $N/A | -$0.14 | -$0.18 | 20% |
| 2018-12-31 | 2019-02-26 | $10 million | -$0.16 | -$0.18 | 11.11% |
| 2018-09-30 | 2018-11-07 | $7.8 million | -$0.05 | -$0.15 | 66.67% |
| 2018-06-30 | 2018-08-01 | $-10000000 | -$0.19 | -$0.19 | -1.77% |
| 2018-03-31 | 2018-05-09 | $10 million | $0.00 | -$0.19 | 101.03% |
| 2017-12-31 | 2018-02-21 | $N/A | -$0.18 | -$0.20 | 10% |
| 2017-09-30 | 2017-11-07 | $N/A | -$0.19 | -$0.19 | 0% |
| 2017-06-30 | 2017-08-02 | $N/A | -$0.18 | -$0.18 | 0% |
| 2017-03-31 | 2017-05-09 | $N/A | -$0.17 | -$0.18 | 3.79% |
| 2016-12-31 | 2017-02-15 | $53000 | -$0.17 | -$0.17 | 0% |
| 2016-09-30 | 2016-11-07 | $70000 | -$0.15 | -$0.14 | -11.11% |
| 2016-06-30 | 2016-08-02 | $496000 | -$0.13 | -$0.17 | 24.99% |
| 2016-03-31 | 2016-05-10 | $93000 | -$0.17 | -$0.15 | -15.88% |
| 2015-12-31 | 2016-02-09 | $8.31 million | -$0.01 | -$0.11 | 91.11% |
| 2015-09-30 | 2015-11-03 | $229000 | -$0.13 | -$0.15 | 13.33% |
| 2015-06-30 | 2015-08-04 | $222000 | -$0.14 | -$0.12 | -16.67% |
| 2015-03-31 | 2015-05-05 | $513000 | -$0.12 | -$0.10 | -20% |
| 2014-12-31 | 2015-02-10 | $6.55 million | -$0.03 | -$0.11 | 72.73% |
| 2014-09-30 | 2014-10-29 | $1.72 million | -$0.11 | -$0.11 | 0% |
| 2014-06-30 | 2014-08-06 | $1.96 million | -$0.05 | -$0.11 | 54.55% |
| 2014-03-31 | 2014-05-19 | $2.13 million | -$0.04 | -$0.10 | 60% |
| 2013-12-31 | 2014-02-11 | $1.78 million | -$0.07 | -$0.12 | 41.67% |
| 2013-09-30 | 2013-10-29 | $1.59 million | -$0.12 | -$0.10 | -20% |
| 2013-06-30 | 2013-08-07 | $22000 | -$0.08 | ||
| 2013-03-31 | 2013-04-25 | $162000 | -$0.09 | ||
| 2012-12-31 | 2013-02-20 | $134000 | -$0.15 | ||
| 2012-09-30 | 2012-11-05 | $108000 | -$0.10 | ||
| 2012-06-30 | 2012-08-07 | $N/A | -$0.02 | ||
| 2012-03-31 | 2012-05-01 | $N/A | -$0.12 | ||
| 2011-12-31 | 2012-02-07 | $N/A | -$0.13 | -$0.10 | -30% |
| 2011-09-30 | 2011-11-08 | $N/A | -$0.10 | -$0.09 | -11.11% |
| 2011-06-30 | 2011-08-02 | $N/A | -$0.06 | -$0.08 | 25% |
| 2011-03-31 | 2011-05-11 | $N/A | -$0.06 | -$0.07 | 14.29% |
| 2010-12-31 | 2011-02-15 | $190000 | -$0.06 | ||
| 2010-09-30 | 2010-10-26 | $-800000 | -$0.05 | ||
| 2010-06-30 | 2010-07-27 | $800000 | -$0.03 | -$0.06 | 50% |
| 2010-03-31 | 2010-04-27 | $125000 | -$0.08 | -$0.05 | -60% |
| 2009-12-31 | 2010-02-09 | $25000 | -$0.07 | -$0.08 | 12.5% |
| 2009-09-30 | 2009-10-27 | $-225000 | -$0.06 | -$0.07 | 14.29% |
| 2009-06-30 | 2009-07-30 | $225000 | $0.08 | ||
| 2009-03-31 | 2009-05-12 | $N/A | -$0.08 | ||
| 2008-12-31 | 2009-02-11 | $11000 | -$0.13 | ||
| 2008-09-30 | 2008-11-13 | $6000 | -$0.12 | ||
| 2008-06-30 | 2008-07-31 | $40000 | -$0.10 | ||
| 2008-03-31 | 2008-05-14 | $281000 | -$0.09 | ||
| 2007-12-31 | 2008-02-19 | $90000 | -$0.11 | ||
| 2007-09-30 | 2007-10-23 | $90000 | -$0.10 | ||
| 2007-06-30 | 2007-08-02 | $N/A | -$0.11 | ||
| 2007-03-31 | 2007-05-01 | $N/A | -$0.11 | ||
| 2006-12-31 | 2007-02-06 | $10000 | -$0.14 | ||
| 2006-09-30 | 2006-11-01 | $-5000 | -$0.09 | ||
| 2006-06-30 | 2006-07-26 | $5000 | -$0.13 | ||
| 2006-03-31 | 2006-04-27 | $200000 | -$0.11 | ||
| 2005-12-31 | 2006-02-09 | $551000 | -$0.12 | ||
| 2005-09-30 | 2005-11-02 | $95000 | -$0.13 | ||
| 2005-06-30 | 2005-07-27 | $70000 | -$0.12 | ||
| 2005-03-31 | 2005-04-20 | $481000 | -$0.13 | ||
| 2004-12-31 | 2005-02-08 | $552000 | -$0.14 | ||
| 2004-09-30 | 2004-11-02 | $971000 | -$0.13 | ||
| 2004-06-30 | 2004-07-20 | $984000 | -$0.12 | ||
| 2004-03-31 | 2004-04-21 | $1.52 million | -$0.11 | ||
| 2003-12-31 | 2004-02-04 | $1.36 million | -$0.13 | ||
| 2003-09-30 | 2003-10-29 | $1.95 million | -$0.12 | ||
| 2003-06-30 | 2003-07-23 | $2.94 million | -$0.09 | ||
| 2003-03-31 | 2003-03-31 | $2.58 million | -$0.09 | ||
| 2002-12-31 | 2002-12-31 | $2.66 million | -$0.12 | ||
| 2002-09-30 | 2002-09-30 | $2.81 million | -$0.12 | ||
| 2002-06-30 | 2002-06-30 | $2.81 million | -$0.11 | ||
| 2002-03-31 | 2002-04-24 | $2.81 million | -$0.12 | -$0.17 | 29.41% |
| 2001-12-31 | 2002-02-13 | $3.09 million | -$0.16 | -$0.19 | 15.79% |
| 2001-09-30 | 2001-10-25 | $3.12 million | -$0.14 | -$0.16 | 12.5% |
| 2001-06-30 | 2001-07-25 | $2.91 million | -$0.15 | -$0.15 | 0% |
| 2001-03-31 | 2001-04-30 | $2.25 million | -$0.14 | -$0.13 | -7.69% |
| 2000-12-31 | 2001-02-14 | $3.43 million | -$0.06 | -$0.08 | 25% |
| 2000-09-30 | 2000-10-31 | $1.57 million | -$0.24 | -$0.16 | -50% |
Compugen Ltd (CGEN) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | 4.31 million |
| Income Before Tax | N/A | N/A | N/A | N/A | -6.46 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 2.38 million |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Ebit | N/A | N/A | N/A | N/A | -6.69 million |
| Operating Income | N/A | N/A | N/A | N/A | -6.69 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 232000 |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | -6.46 million |
| Net Income Applicable to Common Shares | -8.56 million | -7.76 million | -6.25 million | -7.13 million | -6.46 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 15.44 million |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 38.32 million |
| Other Current Liabilities | 668000 | 572000 | N/A | N/A | 774000 |
| Total Assets | N/A | N/A | N/A | N/A | 53.76 million |
| Common Stock | 119.78 million | 127.24 million | 129.47 million | 114.11 million | 38.32 million |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | 5.48 million | 5.55 million | 5.6 million | 5.51 million | 5.65 million |
| Other Assets | 4.74 million | 4.47 million | 3.73 million | 3.59 million | 3.18 million |
| Cash | N/A | N/A | N/A | N/A | 43.88 million |
| Total Current Liabilities | 10.52 million | 7.92 million | N/A | N/A | 6.82 million |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | 4.48 million | 4.75 million | 5.03 million | 5.27 million | 5.59 million |
| Total Current Assets | 129.09 million | 134.14 million | N/A | N/A | 45 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 119.78 million | 127.24 million | 129.47 million | 114.11 million | 38.32 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 9.22 million | 6.83 million | N/A | N/A | 5.45 million |
Compugen Ltd (CGEN) Chart:
Compugen Ltd (CGEN) News:
Below you will find a list of latest news for Compugen Ltd (CGEN) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Compugen Ltd (CGEN) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | 2.5 | 0.1 | CALL | 0 | 35 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.05 | CALL | 0 | 105 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | CALL | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 2.5 | 0.65 | PUT | 0 | 10 | 134.89 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 525.03 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 324.74 | TRUE | 0 | 0 |
| 2024-06-21 | 0.5 | 2.25 | CALL | 0 | 0 | 513.84 | TRUE | 0 | 0 |
| 2024-06-21 | 1 | 1.1 | CALL | 2 | 270 | 797.22 | TRUE | 1.1 | 0 |
| 2024-06-21 | 1.5 | 0.6 | CALL | 0 | 16 | 113.2 | TRUE | 0 | 0 |
| 2024-06-21 | 2 | 0.33 | CALL | 40 | 591 | 113.61 | TRUE | -0.07 | -0.18 |
| 2024-06-21 | 2.5 | 0.2 | CALL | 10 | 2186 | 107.93 | FALSE | -0.02 | -0.09 |
| 2024-06-21 | 5 | 0.03 | CALL | 0 | 655 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 7.5 | 0.05 | CALL | 0 | 351 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 0.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 1 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 1.5 | 0.12 | PUT | 0 | 22 | 0 | FALSE | 0 | 0 |
| 2024-06-21 | 2 | 0.3 | PUT | 0 | 94 | 104.37 | FALSE | 0 | 0 |
| 2024-06-21 | 2.5 | 0.7 | PUT | 0 | 334 | 108.12 | TRUE | 0 | 0 |
| 2024-06-21 | 5 | 2.79 | PUT | 0 | 1 | 233.25 | TRUE | 0 | 0 |
| 2024-06-21 | 7.5 | 0 | PUT | 0 | 0 | 302.93 | TRUE | 0 | 0 |
| 2024-09-20 | 0.5 | 2.3 | CALL | 0 | 5 | 299.49 | TRUE | 0 | 0 |
| 2024-09-20 | 1 | 1.15 | CALL | 0 | 57 | 114.85 | TRUE | 0 | 0 |
| 2024-09-20 | 1.5 | 0.73 | CALL | 0 | 21 | 114.6 | TRUE | 0 | 0 |
| 2024-09-20 | 2 | 0.5 | CALL | 0 | 98 | 95.36 | TRUE | 0 | 0 |
| 2024-09-20 | 2.5 | 0.47 | CALL | 1 | 177 | 113.84 | FALSE | 0.47 | 0 |
| 2024-09-20 | 5 | 0.19 | CALL | 0 | 2946 | 114.68 | FALSE | 0 | 0 |
| 2024-09-20 | 7.5 | 0.15 | CALL | 0 | 654 | 138.08 | FALSE | 0 | 0 |
| 2024-09-20 | 0.5 | 0 | PUT | 0 | 0 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 1 | 0.17 | PUT | 0 | 1 | 0 | FALSE | 0 | 0 |
| 2024-09-20 | 1.5 | 0.29 | PUT | 0 | 3 | 118.57 | FALSE | 0 | 0 |
| 2024-09-20 | 2 | 0.4 | PUT | 0 | 28 | 126.73 | FALSE | 0 | 0 |
| 2024-09-20 | 2.5 | 0.9 | PUT | 0 | 525 | 115.64 | TRUE | 0 | 0 |
| 2024-09-20 | 5 | 0 | PUT | 0 | 0 | 127.28 | TRUE | 0 | 0 |
| 2024-09-20 | 7.5 | 0 | PUT | 0 | 0 | 189.74 | TRUE | 0 | 0 |
| 2024-12-20 | 2.5 | 0.55 | CALL | 0 | 103 | 95.43 | FALSE | 0 | 0 |
| 2024-12-20 | 5 | 0.3 | CALL | 0 | 104 | 131.64 | FALSE | 0 | 0 |
| 2024-12-20 | 7.5 | 0.13 | CALL | 0 | 1 | 123.4 | FALSE | 0 | 0 |
| 2024-12-20 | 2.5 | 0 | PUT | 0 | 0 | 127.6 | TRUE | 0 | 0 |
| 2024-12-20 | 5 | 0 | PUT | 0 | 0 | 127.07 | TRUE | 0 | 0 |
| 2024-12-20 | 7.5 | 0 | PUT | 0 | 0 | 124.4 | TRUE | 0 | 0 |
Latest CGEN Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 12 | $1.605 |
| Jun 13, 2022 7:59 PM EST | 10 | $1.61 |
| Jun 13, 2022 7:59 PM EST | 3 | $1.61 |
| Jun 13, 2022 7:59 PM EST | 13 | $1.61 |
| Jun 13, 2022 7:59 PM EST | 100 | $1.62 |
Compugen Ltd (CGEN) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320001688/0001178913-20-001688-index.htm |
| 2016-08-26 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1119774/000000000016090139/0000000000-16-090139-index.htm |
| 2016-09-07 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1119774/000000000016091776/0000000000-16-091776-index.htm |
| 2016-10-05 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1119774/000000000016095978/0000000000-16-095978-index.htm |
| 2019-08-07 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1119774/000000000019012150/0000000000-19-012150-index.htm |
| 2020-08-05 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1119774/000000000020007121/0000000000-20-007121-index.htm |
| 2018-06-22 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1119774/000090266418002655/0000902664-18-002655-index.htm |
| 2019-01-17 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1119774/000090266419000272/0000902664-19-000272-index.htm |
| 2017-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1119774/000092189517000380/0000921895-17-000380-index.htm |
| 2018-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1119774/000092189518000594/0000921895-18-000594-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1119774/000092189519000368/0000921895-19-000368-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1119774/000095010320002666/0000950103-20-002666-index.htm |
| 2020-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1119774/000110465920021148/0001104659-20-021148-index.htm |
| 2020-10-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1119774/000110465920113840/0001104659-20-113840-index.htm |
| 2019-09-06 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1119774/000114036119016284/0001140361-19-016284-index.htm |
| 2020-02-12 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1119774/000114036120002909/0001140361-20-002909-index.htm |
| 2019-02-14 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1119774/000114420419007785/0001144204-19-007785-index.htm |
| 2016-09-21 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1119774/000117891316006541/0001178913-16-006541-index.htm |
| 2016-10-06 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1119774/000117891316006634/0001178913-16-006634-index.htm |
| 2016-10-06 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1119774/000117891316006636/0001178913-16-006636-index.htm |
| 2016-10-14 | 424B2 | Prospectus [Rule 424(b)(2)] | https://www.sec.gov/Archives/edgar/data/1119774/000117891316006669/0001178913-16-006669-index.htm |
| 2016-11-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891316006774/0001178913-16-006774-index.htm |
| 2016-11-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891316006863/0001178913-16-006863-index.htm |
| 2016-12-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891316007098/0001178913-16-007098-index.htm |
| 2016-12-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891316007100/0001178913-16-007100-index.htm |
| 2017-02-01 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1119774/000117891317000261/0001178913-17-000261-index.htm |
| 2017-02-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317000484/0001178913-17-000484-index.htm |
| 2017-02-16 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317000548/0001178913-17-000548-index.htm |
| 2017-03-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317000929/0001178913-17-000929-index.htm |
| 2017-05-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317001335/0001178913-17-001335-index.htm |
| 2017-05-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317001604/0001178913-17-001604-index.htm |
| 2017-05-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317001639/0001178913-17-001639-index.htm |
| 2017-05-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317001674/0001178913-17-001674-index.htm |
| 2017-07-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317002033/0001178913-17-002033-index.htm |
| 2017-07-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317002041/0001178913-17-002041-index.htm |
| 2017-07-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317002137/0001178913-17-002137-index.htm |
| 2017-08-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317002234/0001178913-17-002234-index.htm |
| 2017-09-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317002626/0001178913-17-002626-index.htm |
| 2017-10-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317002839/0001178913-17-002839-index.htm |
| 2017-11-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317003018/0001178913-17-003018-index.htm |
| 2017-11-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317003052/0001178913-17-003052-index.htm |
| 2017-12-18 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891317003409/0001178913-17-003409-index.htm |
| 2018-01-31 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318000326/0001178913-18-000326-index.htm |
| 2018-02-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318000371/0001178913-18-000371-index.htm |
| 2018-02-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318000663/0001178913-18-000663-index.htm |
| 2018-03-14 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318000832/0001178913-18-000832-index.htm |
| 2018-03-27 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318000965/0001178913-18-000965-index.htm |
| 2018-03-27 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1119774/000117891318000967/0001178913-18-000967-index.htm |
| 2018-04-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318001068/0001178913-18-001068-index.htm |
| 2018-04-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318001300/0001178913-18-001300-index.htm |
| 2018-05-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318001533/0001178913-18-001533-index.htm |
| 2018-05-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318001755/0001178913-18-001755-index.htm |
| 2018-05-25 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318001757/0001178913-18-001757-index.htm |
| 2018-06-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318001832/0001178913-18-001832-index.htm |
| 2018-06-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318001882/0001178913-18-001882-index.htm |
| 2018-06-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318001911/0001178913-18-001911-index.htm |
| 2018-06-18 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318001921/0001178913-18-001921-index.htm |
| 2018-06-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318001935/0001178913-18-001935-index.htm |
| 2018-06-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318001997/0001178913-18-001997-index.htm |
| 2018-07-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318002015/0001178913-18-002015-index.htm |
| 2018-08-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318002228/0001178913-18-002228-index.htm |
| 2018-08-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318002303/0001178913-18-002303-index.htm |
| 2018-09-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318002480/0001178913-18-002480-index.htm |
| 2018-09-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318002500/0001178913-18-002500-index.htm |
| 2018-09-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318002554/0001178913-18-002554-index.htm |
| 2018-10-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318002656/0001178913-18-002656-index.htm |
| 2018-10-16 | D | Notice of Exempt Offering of Securities | https://www.sec.gov/Archives/edgar/data/1119774/000117891318002674/0001178913-18-002674-index.htm |
| 2018-11-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891318002831/0001178913-18-002831-index.htm |
| 2019-02-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891319000683/0001178913-19-000683-index.htm |
| 2019-03-21 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1119774/000117891319000894/0001178913-19-000894-index.htm |
| 2019-05-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891319001548/0001178913-19-001548-index.htm |
| 2019-07-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891319001803/0001178913-19-001803-index.htm |
| 2019-08-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891319002031/0001178913-19-002031-index.htm |
| 2019-08-05 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1119774/000117891319002034/0001178913-19-002034-index.htm |
| 2019-08-08 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1119774/000117891319002131/0001178913-19-002131-index.htm |
| 2019-09-19 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891319002372/0001178913-19-002372-index.htm |
| 2019-11-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891319002571/0001178913-19-002571-index.htm |
| 2019-11-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891319002584/0001178913-19-002584-index.htm |
| 2019-11-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891319002693/0001178913-19-002693-index.htm |
| 2020-01-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320000073/0001178913-20-000073-index.htm |
| 2020-02-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320000606/0001178913-20-000606-index.htm |
| 2020-02-20 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320000610/0001178913-20-000610-index.htm |
| 2020-02-24 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320000625/0001178913-20-000625-index.htm |
| 2020-02-27 | 20-F/A | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320000674/0001178913-20-000674-index.htm |
| 2020-03-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320000757/0001178913-20-000757-index.htm |
| 2020-03-11 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320000777/0001178913-20-000777-index.htm |
| 2020-03-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320000779/0001178913-20-000779-index.htm |
| 2020-03-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320000783/0001178913-20-000783-index.htm |
| 2020-03-12 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320000804/0001178913-20-000804-index.htm |
| 2020-03-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320000808/0001178913-20-000808-index.htm |
| 2020-03-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320000830/0001178913-20-000830-index.htm |
| 2020-04-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320001028/0001178913-20-001028-index.htm |
| 2020-04-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320001122/0001178913-20-001122-index.htm |
| 2020-04-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320001209/0001178913-20-001209-index.htm |
| 2020-05-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320001331/0001178913-20-001331-index.htm |
| 2020-05-27 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320001627/0001178913-20-001627-index.htm |
| 2020-06-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320001688/0001178913-20-001688-index.htm |
| 2020-07-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320002175/0001178913-20-002175-index.htm |
| 2020-07-30 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1119774/000117891320002176/0001178913-20-002176-index.htm |
| 2020-07-30 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1119774/000117891320002178/0001178913-20-002178-index.htm |
| 2020-08-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320002260/0001178913-20-002260-index.htm |
| 2020-08-05 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1119774/000117891320002275/0001178913-20-002275-index.htm |
| 2020-09-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320002571/0001178913-20-002571-index.htm |
| 2020-09-17 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320002651/0001178913-20-002651-index.htm |
| 2020-11-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1119774/000117891320003012/0001178913-20-003012-index.htm |
| 2019-09-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1119774/000121465919005716/0001214659-19-005716-index.htm |
| 2016-10-11 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1119774/999999999516005936/9999999995-16-005936-index.htm |
| 2019-08-12 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1119774/999999999519001867/9999999995-19-001867-index.htm |
| 2020-08-07 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1119774/999999999520002082/9999999995-20-002082-index.htm |
| 2017-08-14 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1119774/999999999717008067/9999999997-17-008067-index.htm |
| 2018-05-18 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1119774/999999999718005801/9999999997-18-005801-index.htm |
| 2018-09-04 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1119774/999999999718007616/9999999997-18-007616-index.htm |
| 2018-12-04 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1119774/999999999718009265/9999999997-18-009265-index.htm |
| 2019-05-30 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1119774/999999999719005279/9999999997-19-005279-index.htm |